Nektar Therapeutics Surpasses Q4 Revenue and EPS Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NKTR?
Source: seekingalpha
- Performance Beat: Nektar Therapeutics saw a 6% increase in early trading on Friday, reporting a GAAP EPS of -$1.78 for Q4, surpassing estimates by $0.69, while revenue of $21.81 million exceeded expectations by $11.4 million, indicating a positive shift in financial performance.
- Annual Revenue Decline: Despite the strong Q4 results, total revenue for 2025 was $55.2 million, significantly down from $98.4 million in 2024, primarily due to the cessation of product sales following the sale of the Huntsville manufacturing facility, highlighting the impact of strategic divestitures on revenue.
- Significant R&D Progress: CEO Howard W. Robin noted that 2025 was pivotal, with promising Phase 2 data for rezpegaldesleukin in atopic dermatitis and alopecia areata, with plans to initiate a Phase 3 trial in June 2026, further advancing product development.
- Optimistic Financial Outlook: CFO Sandra Gardiner provided preliminary guidance for 2026, expecting non-cash royalty revenue between $40 million and $45 million, R&D expenses of $200 million to $250 million, and an end-of-year cash and investments target of $400 million to $460 million, reflecting improved financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.360
Low
102.00
Averages
123.43
High
165.00
Current: 70.360
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Highlights from Q4 2025 Earnings Call
- Clinical Progress of REZPEG: Nektar Therapeutics reported positive results from Phase IIb studies of REZPEG for atopic dermatitis and alopecia areata in Q4 2025, with significant increases in EASI-75 and EASI-90 scores, indicating its potential in treating inflammatory diseases and positioning the company favorably in a narrowing competitive landscape.
- Strong Financial Position: By the end of 2025, the company had $245.8 million in cash and investments with no debt, and subsequently raised approximately $476 million in net cash, providing ample funding for the upcoming Phase III trials, with expectations to end 2026 with $400 million to $460 million in cash and investments.
- Revenue and Expense Overview: The company reported $21.8 million in revenue for Q4 2025 and $55.2 million for the full year, despite a net loss of $36.1 million, reflecting ongoing investments in R&D and marketing, with projected R&D expenses for 2026 expected to be between $200 million and $250 million.
- Market Outlook and Strategy: Management expressed confidence in REZPEG's unique efficacy and safety profile, planning to initiate Phase III trials in June 2026, emphasizing REZPEG's differentiated competitive advantage in the atopic dermatitis market, which is expected to drive future market share growth.
See More
Faruqi & Faruqi Investigates Nektar Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics for investors who purchased or acquired securities between February 26, 2025, and December 15, 2025, urging them to seek lead plaintiff status by the May 5, 2026 deadline.
- Trial Result Failure: Nektar's press release on December 16, 2025, revealed that the REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, closing at $49.16 per share, highlighting significant management failures in clinical trial oversight.
- False Statement Allegations: The complaint alleges that Nektar and its executives violated federal securities laws by failing to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards, likely leading to significant negative impacts on trial results, thus rendering public statements materially false and misleading.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Nektar's conduct, including whistleblowers and former employees, to contact the firm directly to provide legal support for affected investors and ensure their rights are protected.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket fees, highlighting the legal avenue's role in protecting and compensating affected investors.
- Details of Allegations: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially undermining investor confidence.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and expertise in handling such cases.
See More
Nektar Therapeutics (NKTR.US) Insider Plans to Sell $5.7 Million in Common Stock via Form 144
Stock Sale Announcement: Nektar Therapeutics plans to sell 78,510 shares of its common stock on March 13.
Market Value: The total market value of the shares being sold is approximately $5.7 million.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific Corporation (NYSE:BSX) faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the period from July 23, 2025, to February 3, 2026, which has severely undermined investor confidence and could negatively impact its stock performance.
- Eos Energy Lawsuit: Eos Energy Enterprises (NASDAQ:EOSE) is accused of not achieving the necessary production ramp-up during the class period from November 5, 2025, to February 26, 2026, with battery line downtimes exceeding industry norms, potentially leading to diminished investor expectations and market confidence.
- Soleno Therapeutics Lawsuit: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is facing a class action lawsuit for allegedly concealing significant safety concerns related to its DCCR clinical trial, which could raise doubts about the commercial viability of its product and adversely affect its market performance and stock price.
- Nektar Therapeutics Lawsuit: Nektar Therapeutics (NASDAQ:NKTR) is accused of not adhering to trial protocols during the period from February 26 to December 15, 2025, which may negatively impact the integrity of its REZOLVE-AA trial results, further eroding investor confidence in its future prospects.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26 and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who choose not to act will remain absent class members and may forfeit their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for free consultations to discuss their rights and potential recovery options.
See More
Nektar Therapeutics Highlights from Q4 2025 Earnings Call
- Clinical Progress of REZPEG: Nektar Therapeutics reported positive results from Phase IIb studies of REZPEG for atopic dermatitis and alopecia areata in Q4 2025, with significant increases in EASI-75 and EASI-90 scores, indicating its potential in treating inflammatory diseases and positioning the company favorably in a narrowing competitive landscape.
- Strong Financial Position: By the end of 2025, the company had $245.8 million in cash and investments with no debt, and subsequently raised approximately $476 million in net cash, providing ample funding for the upcoming Phase III trials, with expectations to end 2026 with $400 million to $460 million in cash and investments.
- Revenue and Expense Overview: The company reported $21.8 million in revenue for Q4 2025 and $55.2 million for the full year, despite a net loss of $36.1 million, reflecting ongoing investments in R&D and marketing, with projected R&D expenses for 2026 expected to be between $200 million and $250 million.
- Market Outlook and Strategy: Management expressed confidence in REZPEG's unique efficacy and safety profile, planning to initiate Phase III trials in June 2026, emphasizing REZPEG's differentiated competitive advantage in the atopic dermatitis market, which is expected to drive future market share growth.
See More
Faruqi & Faruqi Investigates Nektar Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics for investors who purchased or acquired securities between February 26, 2025, and December 15, 2025, urging them to seek lead plaintiff status by the May 5, 2026 deadline.
- Trial Result Failure: Nektar's press release on December 16, 2025, revealed that the REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, closing at $49.16 per share, highlighting significant management failures in clinical trial oversight.
- False Statement Allegations: The complaint alleges that Nektar and its executives violated federal securities laws by failing to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards, likely leading to significant negative impacts on trial results, thus rendering public statements materially false and misleading.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Nektar's conduct, including whistleblowers and former employees, to contact the firm directly to provide legal support for affected investors and ensure their rights are protected.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket fees, highlighting the legal avenue's role in protecting and compensating affected investors.
- Details of Allegations: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially undermining investor confidence.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and expertise in handling such cases.
See More
Nektar Therapeutics (NKTR.US) Insider Plans to Sell $5.7 Million in Common Stock via Form 144
Stock Sale Announcement: Nektar Therapeutics plans to sell 78,510 shares of its common stock on March 13.
Market Value: The total market value of the shares being sold is approximately $5.7 million.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific Corporation (NYSE:BSX) faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the period from July 23, 2025, to February 3, 2026, which has severely undermined investor confidence and could negatively impact its stock performance.
- Eos Energy Lawsuit: Eos Energy Enterprises (NASDAQ:EOSE) is accused of not achieving the necessary production ramp-up during the class period from November 5, 2025, to February 26, 2026, with battery line downtimes exceeding industry norms, potentially leading to diminished investor expectations and market confidence.
- Soleno Therapeutics Lawsuit: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is facing a class action lawsuit for allegedly concealing significant safety concerns related to its DCCR clinical trial, which could raise doubts about the commercial viability of its product and adversely affect its market performance and stock price.
- Nektar Therapeutics Lawsuit: Nektar Therapeutics (NASDAQ:NKTR) is accused of not adhering to trial protocols during the period from February 26 to December 15, 2025, which may negatively impact the integrity of its REZOLVE-AA trial results, further eroding investor confidence in its future prospects.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26 and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who choose not to act will remain absent class members and may forfeit their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for free consultations to discuss their rights and potential recovery options.
See More
